Related Experiment Video

Updated: Jun 23, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Renovascular hypertension: treatment by percutaneous transluminal dilatation

U Kuhlmann, W Vetter, J Furrer

    Annals of Internal Medicine
    |January 1, 1980
    PubMed

    Insights

    Percutaneous transluminal dilatation effectively treated renovascular hypertension in most patients. This minimally invasive procedure improved or cured hypertension, with sustained vessel patency in the majority after six months.

    Area of Science:

    • Cardiology
    • Nephrology
    • Interventional Radiology

    Background:

    • Renovascular hypertension significantly impacts patient health.
    • Surgical and medical treatments have limitations.
    • Percutaneous transluminal dilatation offers a minimally invasive alternative.

    Purpose of the Study:

    • To evaluate the efficacy and safety of percutaneous transluminal dilatation for unilateral renovascular hypertension.
    • To assess long-term outcomes including blood pressure control and renal artery patency.

    Main Methods:

    • Eight patients with unilateral renovascular hypertension underwent percutaneous transluminal dilatation.
    • Stenoses were attributed to atherosclerosis or fibromuscular hyperplasia.
    • Follow-up included clinical assessment and renal angiography at 6 months.

    Main Results:

    • Seven of eight patients experienced hypertension improvement or cure.
    • Mean pressure gradient across stenoses decreased significantly post-procedure.
    • Renal angiography showed vessel patency in five of six patients at 6 months.

    Conclusions:

    • Percutaneous transluminal dilatation is a valuable treatment for renovascular hypertension.
    • The procedure demonstrates favorable outcomes and acceptable safety profile.
    • Further research can explore its role in diverse patient populations.

    More Related Videos

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

    Published on: June 6, 2025

    Related Concept Videos

    Antihypertensive Drugs: Vasodilators01:23

    Antihypertensive Drugs: Vasodilators

    Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...